Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29243860 | 0.91 | HTT (0.65) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL21082280 | 0.89 | MEN1 (0.64) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL8102334 | 0.87 | HTT (0.59) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL19899411 | 0.85 | HTT (0.59) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL3358984 | 0.82 | HTT (0.75) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL8106191 | 0.81 | HTT (0.70) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL3357703 | 0.81 | HTT (0.73) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL20382948 | 0.80 | HTT (0.68) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL20382958 | 0.80 | HTT (0.71) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL9511604 | 0.80 | HTT (0.58) | HTTSMN1; SMN2MEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169126-A1 | POLYMERIC METAL CHELATING COMPOSITIONS AND METHODS OF PREPARING SAME FOR CONTROLLING GROWTH AND ACTIVITIES OF LIVING CELLS AND ORGANISMS | CHELATION PARTNERS INCORPORATED (CA) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169126-A1 | POLYMERIC METAL CHELATING COMPOSITIONS AND METHODS OF PREPARING SAME FOR CONTROLLING GROWTH AND ACTIVITIES OF LIVING CELLS AND ORGANISMS | PICALM, HMBS, TFRC | HTT 3362/4885SMN1; SMN2 2683/4885MEN1 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.